Symptomatology and and Dermal inflammation

Charoen Choonhakarn, MD
Division of Dermatology
Departmet of Medicine
Khon kaen University

Objectives of Dermal Inflammation

- Understand and able to use dermatologic terminology appropriately
- · Able to describe the skin lesions correctly
- Understand pathogenesis, clinical manifestations, natural history and principle of the treatments of the following skin disorders
- 1. Papulosquamous diseases
- 2. Urticaria
- 3. Alopecia
- 4. Acne
- 5. Erythema multiforme
- 6. Steven-Johnson syndrome
- 7. Toxic epidermal necrolysis

References

- 1. Fitzpatrick's Dermatology in General Medicine: 2 volumes
- 2. Bolognia; Dermatology: 2 volumes
- 3. Rook; Textbook of Dermatology: 4 volumes

Symptomatology


- · Skin lesions**
- Itching
- · Pain/burning
- · Anesthesia

How to diagnose skin disorders?




- 1. Skin lesions
- 2. Configuration
- 3. Location of the lesions
- 4. Distribution of the lesions

Classification of skin lesions




Primary skin lesions arise from previously normal skin classified morphologically as macules, papules, plaques, patches, nodules, tumors, wheals, cysts, vesicles,

Classification of skin lesions



Secondary skin

lesions lesions arise as a consequence of rupture, mechanical irritation, extension, invasion, normal and abnormal healing eg. erosion, ulcer, fissure, crust, scale, lichenification, excoriation, scar, keloid




Blister












Lichenification

































Configuration of skin disorders


- -Annular or arciform or polycyclic: tinea coporis, pityriasis versicolor, leprosy, psoriasis, subacute cutaneous lupus erythematosus (SCLE), granuloma annulare
- -Linear: excoriation, psoriasis, scabies
- -Zosteriform: herpes zoster
- -Iris or target: erythema multiforme
- -Herpetiform: herpes simplex



















Configuration of skin disorders

- -Morbilliform: measles, drug eruption
- -Discrete
- -Confluent
- -Reticulate: livedo reticularis, lichen planus
- -Serpiginous: creeping eruption
- -Oval: nummular eczema, fixed drug eruption, psoriasis










Serpiginous

Target lesion

Color of the lesions

- Violaceous or purplish: discoid LE, Gottron's papules in dermatomyositis, lichen planus, Kaposi's sarcoma
- · Green: Pseudomonas infection of nail
- · Yellow: xanthoma, xanthelasma
- Black: melanoma, pigmented BCC, mole, seborrheic keratosis
- Hyperpigmented: melasma, pityriasis versicolor, postinflammatory hyperpigmentation
- White: vitiligo
- Hypopigmented: P. versicolor, P. alba, indeterminate or tuberculoid leprosy, postinflammatory hypopigmentation
- · Red: psoriasis, cellulitis





Green nail: Pseudomonas infection

Black nodule: malignant melanoma



Violaceous papules : Kaposi's sarcoma



Depigmentation: vitiligo



Yellowish nodule: xanthoma

Scale

- Thick silvery scale: psoriasis
- Fine wrinkle scale: pityriasis versicolor
- Fish-like scale: ichthyosis
- · Greasy scale: seborrheic dermatitis
- · Collarette scale: pityriasis rosea
- · Trailing scale: erythema annulare centrifugum




Fine wrinkle scale: pityriasis versicolor



Collarette scale: pityriasis rosea



Trailing scale: erythema annulare centrifugum



Fish-like scale: ichthyosis




Greasy scale: seborrheic dermatitis



Thick silvery scale: psoriasis


Seborrheic dermatitis **Psoriasis** Solar lentigo Xanthelasma Melasma Melasma
Solar keratosis (in exposed area

525 Actinic keratosis Basal cell carcinoma quamous cell carcinoma Acne Seborrheic keratosis Seborrheic dermatitis Venous lake Perleche Acrochordon Herpes labialis (skin tags) Seborrheic dermatitis Spider angioma Common acquired Cherry angioma melanocytic nevus Atopic eczematous Dysplastic nevus dermatitis Psoriasis Eczematous dermatitis Verruca vulgaris Dermatofibroma Candidiasis Tinea cruris **Psoriasis Psoriasis** Lichen simplex Malignant melanoma (female) Ichthyosis Stasis dermatitis Stasis ulcer Fungal infection (Tinea pedis, interdigital) Fungal infections Racial pigmentation (onychomycosis) (gums and buccal mucosae) Leukoplakia Candidiasis Lichen planus Fissured tongue Migratory glossitis




Distribution of the lesions

- Along skin crease (Christmas tree pattern): pityriasis rosea, psoriasis, pityriasis lichenoides, Kaposi's sarcoma
- Photodistribution: sparing areas(periorbital, nasolabial, below chin, flexural areas): drug allergy, CNT disease
- Air-borne distribution: no sparing area: air-borne contact dermatitis
- Axillae, umbilicus, perineum, toe and finger webs: scabiasis



Christmas tree pattern





Photodistribution



Photodistribution

Maculopapular rash: (exanthematous)

- 1. drug eruption
- 2. autoimmune disease
- 3. systemic infection viral exanthem



Describe skin lesions

- Primary skin lesions
- Surface change or secondary lesion eg. scale, erosion
- · Color
- · Configuration for specific disease
- Location
- Distribution



White reticular lesion: oral lichen planus



Annular erythematous patchs: tinea corporis



Target-like papules with central vesicles : erythema multiforme

Papulosquamous disease

- 1. Eczema
- 2. Psoriasis
- 3. Pityriasis rosea

Classification 3 stages

- 1. Acute-vesiculobullous, serum oozing
- 2. Subacute-crusting, scaly plaque
- 3. Chronic-lichenified, hyperkeratotic plaque







Eczema

Endogenous

- Atopic dermatitis
- Seborrheic dermatitis
- Nummular dermatitis
- Dyshidrosis
- Prurigo nodularis
- Lichen simplex chronicus
- Stasis

Exogenous (contact)

Related to ultraviolet

- Phototoxic CD
- Photoallergic CD

Not related to ultraviolet

- Irritant CD
- · Allergic CD

Atopic dermatitis

3 phases

1. Infant : 2 months-2 years

2.Childhood: 3-11years

3. Adult : 12-30 years

Atopic dermatitis, allergic rhinitis, asthma

"Atopic march"

Atopic dermatitis

ESSENTIAL FEATURES—Must be present:

- Pruritus
- Eczema (acute, subacute, chronic)
 - -Typical morphology and age-specific patterns*
 - -Chronic or relapsing history

*Patterns include:

- 1. Facial, neck, and extensor involvement in infants and children
- 2. Current or previous flexural lesions in any age group
- 3. Sparing of the groin and axillary regions

IMPORTANT FEATURES—Adding support to the diagnosis:

- · Early age of onset
- Atopy: personal and/or family history, Ig E reactivity
- · Xerosis

Atopic dermatitis

Pathogenesis: complex interaction of

- 1. Skin barrier disruption: impaired filaggrin, reduced ceramide level, increased transepidermal water loss
- 2. Genetic: uncertain inheritance pattern (AD adult-60% children with AD, both AD parents-81% AD children)
- 3. Environmental: infection (S. aureus, pityrosporum sp.), food, inhalants, season, clothing, stress
- 4. Immunologic factor: IgE, Th1, Th2, Th17



2. Seborrheic dermatitis

greasy scale erythema on face, scalp (dandruff), chest wall, upper back, axillae and inguinal area

Risk: HIV patient, stroke, facial palsy, parkinsonism



3. <u>Dyshidrotic dermatitis (pompholyx)</u>

deep-seated vesicles (sago grain) on palm and sole

Risk: nickle allergy, stress





4. Prurigo nodularis

indurated, hyperkeratotic, excoriated papules on

extremities



5. <u>Lichen simplex chronicus</u> lichenified plaque usually on ankels and knees





6. Stasis dermatitis

brownish or purpuric scaly patch commonly located on medial side of ankles

Risk: venous insufficiency



7. Asteatotic or xerotic dermatitis

fish-like scale and cracking skin, usually on flank, thighs, and legs

Risk: atopy, elder, ichthyosis, malnutrition



8. Nummular dermatitis

Coin-shaped lesion, vary in size





Id reaction:

Autosensitization from pre-existing eczematous lesions presenting with generalized papulvesicles

Nummular dermatitis with Id eruption

Contact dermatitis

- 1. Irritant contact dermatitis or phototoxic dermatitis
- 2. Allergic contact dermatitis or photoallergic dermatitis

Differentiation between irritant and allergic contact dermatitis

Feature	Allergic	Irritant
Susceptibility Duration Remission after discotinuing	Somebody 7-14 d Slow	Everybody 0-2 d Rapid
Symptoms Icthing Pain/burning Concentration of agent Stimulating agent Patch test	++++(early) ++ - Ag and T cell Positive	+++ (late) ++++ (early) High Keratinocytes Negative

Allergic contact dermatitis

Pathogenesis:

- ·Delayed, cell-mediated hypersensitivity
- -Langerhans cell (Ag-presenting cell) in epidermis
- -T cell (MHC class II) in lymph node -Sensitized T cells back to skin

Allergic contact dermatitis

Lesion usually develop after 1-wk exposure to allergen, predominate itching

Clinical: depend on stage of lesion, acute-vesicles, subacute-scaly plaque, chronic-lichenified plaques

Common allergens: nickle, rubber, fragrance, formaldehyde


Confirmation: Patch test




Patch test (allergic CD)











Irritant contact dermatitis

- -Occur within hours or days after exposure
- -Depend on concentration of chemical agents
- -Clinical: burn-like lesion (high conc.) or dry, scaly plaque with fissure (low conc.)
- -Usually seen in person with chronic exposure to water
- -Paederus dermatitis from chemical substance in Rove beetle presenting with vesicles or pustules



Eczema treatment

- -Wet compression (acute)
- -Topical corticosteroids (acute, subacute, chronic)
- -Antihistamines
- -Intralesional corticosteroids (chronic)
- -Keratolytics eg. salicylic or urea (chronic)
- -Systemic corticosteroids
- -Emollients
- -Avoidance: contact dermatitis
- -Advice

Psoriasis vulgaris

- Chronic inflammatory disease, not cure, genetic influence
- · Common association: metabolic syndrome

Clinical features:


- 1.5kin: well-demarcated erythematous plaques with silvery scale on trunk, scalp, extremities
- 2. Nail: pits, oil spots, oncholysis, subungual hyperkeratosis
- 3 Arthritis: small large axial joints

Psoriasis vulgaris


Unknown exact etiology

- 1. Alteration of cell kinetics of keratinocytes (311 vs 36 hr)
- 2. CD8+ T cells
- 3. Cytokines from Th1, Th17
- 4. Environmental factor: physical trauma (Koebner phenomenon), drugs, stress, infection, alcohol ingestion

Current model of psoriasis pathogenesis



Cytokine environment regulates CD4+ T-cell differentiation into functional subsets



Precipitating factors

- 1. Trauma "Koebner phenomenon"
- 2. Infection esp. Streptoccous infection, HIV
- 3. Stress
- 4. Drug eg. chloroquine, beta-blocker, lithium, NSAIDs, steroid withdrawal (pustular psoriasis)
- 5. Alcohol drinking, smoking

Classification

- 1. Chronic plaque; "psoriasis vulgaris"
- 2. Guttate; papule
- 3. Erythrodermic; diffuse
- 4. Pustular; localized or generalized
- 5. Inverse; flexural area
- 6. Nail; oil spot, pits, subungual hyperkeratosis, onycholysis
- 7. Arthritis/enthesopathy



Chronic plaque type





Guttate type



Erythrodermic psoriasis





Pustular type, generalized



Palmoplantar pustular psoriasis





Inverse psoriasis





Pits / Oil spot / Subungual hyperkeratosis



Leukonuchia

Pustular nails

Psoriasis treatment

Mild: PASI or BSA <10%

- Topical corticosteroids or vitamin D3 analogue eg. calcipotriol
- Keratolytics eg salicylic or urea
- · Coal tar, topical vitamin A

Moderate: 10-30%, Severe: > 30%

- Systemic agents eg. methotrexate, cyclosporine, acitretin, biologics
- Phototherapy: UVA or UVB


Pityriasis rosea

- -Age 10-35 years, male = female
- -Course: 6-8 weeks
- -Unknown etiology: infectious agents:HHV-7, sometimes HHV-6
- -DDX; -PR-like drug eruption eg. barbiturates, captopril, gold, metronidazole, clonidine, bismuth
 - -Secondary syphilis

Clinical features

- -Round or oval erythematous papules or plaques with collarette scale
- -Herald patch or primary medallion or mother patch: 50-90%
- -Trunk along skin creases "Christmas tree"
- -Itching 75%
- -Prodome: fever, malaise, arthralgia, lymphadenopathy
- -Rx: topical steroids, antihistamine, acyclovir





Urticaria

Definition: appearance of wheal and/or angioedema Wheal:

- 1. Central swelling of variable size surrounded by a reflex erythema
- 2. Itching, sometimes burning
- 3. Fleeting nature, returning to normal appearance, usually within 1-24 hr

Angioedema:

- 1. Sudden, pronounced swelling of the lower dermis and subcutis
- 2. Frequent mucous membrane
- 3. Resolution slower than for wheal and can take up to 72 hr








Urticaria

Angioedema



Classification



Acute urticaria

2/3 of urticaria

- Causes: contact, insect bite (papular urticaria), drugs, foods, viral infection of upper respiratory tract
- 20-30% progress to chronic urticaria

Chronic urticaria

- Causes: idiopathic, infections (viral hepatitis, Helicobacter pylori, parasites), physical, systemic diseases (SLE, neoplasm)
- · Chronic spontaneous urticaria (CSU)
 - Chronic persistent
 - Chronic intermittent
- · Inducible urticaria
 - Dermographism, cold, delayed pressure, solar, heat, vibratory
- Special types
 - Cholinergic, contact, aquagenic, adrenergic



Adrernergic urticaria



Dermographism



Cholinergic urticaria




Cold urticaria



Dermographism









Papular urticaria

hypersensitivity reaction to the bites of mosquitoes, fleas, bedbugs, and other insects

Individual papules may surround a wheal and display a central punctum



Urticarial vasculitis

- urticaria that persist for> 24 hr
- Appear hyperpigmentation after healing

Mechanism


- 1. Immunologic
- IgE-meadiated (type I)
- 2. Non-immunologic
- Direct mast cell degranulation eg. opiate, plymyxin B, radiocontrast media
- Arachidonic acid metabolism eg. aspirin, NSAIDs


Pathogenesis

- Light Chain


 Ce3
 Binding Site to ForRI

 Heavy Chain
- Mast cell: principal effector cell
 - Express high-affinity IgE receptors (FcεRIs)






Urticaria pathogenesis



Diagnosis algorithm for urticaria



Recommended diagnostic test

Spontaneous	Routine diagnostic tests	Extended diagnostic tests
Acute urticaria	None	None
Chronic urticaria	CBC,ESR or CRP	Autologous serum skin test, Test for infectious diseases (H. pylori, HBV, HCV), Thyroid function and antibodies, Pseudoallergen- free diet for 3 weeks, Skin biopsy, ANA

Recommended diagnostic test

Inducible	Routine diagnostic tests	Extended diagnostic tests
Acquired cold	Cold provocation (ice cube for 20 mins)	Differential blood count, ESR, CRP, cryoproteins
Delayed pressure	Pressure test (0.2-1.5 kg/cm² for 10-20 mins	None
Heat	Heat provocation	None
Solar	UV and visible light of different wavelengths	Rule out other light- induced dermatosis
Dermographic	Elicit dermographism	Differential blood count, ESR, CRP

Recommended diagnostic test

Other urticaria	Routine diagnostic tests	Extended diagnostic tests
Aquagenic	Wet cloths at body temp for 20 mins	None
Cholinergic	Exercise and hot bath provocation	None
Contact	Prick test read after 20 mins	None
Exercise- induced	According to history exercise test with/without food	None

Management

- Identification and elimination of underlying causes
- Avoidance or elimination of the eliciting stimulus
- Inhibition of mast cell mediators

Inhibition of mast cell mediators

 1st generation H1antihistamines for acute urticaria

(chlorpheniramine, hydroxyzine)

 2nd generation or non/less-sedating H1antihistamines (cetirizine, levocetirizine, loratidine, desloratidine, rupatadine, bilastine, fexofenadine)

considered <u>as first-line treatment</u> for chronic urticaria

Erythema multiforme (EM)

Typical targets:

- <3 cm
- regular round shape
- · well-defined border
- at least 3 different zones
- 2 concentric rings1 palpable edematous ring



Erythema multiforme

- EM minor (mild cutaneous syndrome): associated with HSV, mycoplasma infection, drugs
- EM major (more severe form / involve mucous membrane): drug-induced (antibiotics, anticonvulsants, NSAIDs)



Typical targets

Stevens-Johnson Syndrome (SJS) Toxic Epidermal Necrolysis (TEN)

- Raised <u>atypical</u> targets: round, edematous, palpable lesion, only 2 zones and/or poorly defined border
- Flat <u>atypical</u> targets: potential central blister
- Macules with or without blister: nonpalpable, erythematous or purpuric, irregular shape and size





Flat atypical targets

Classification SJS/TEN

Classification	Bullous EM	SJS	Overlap SJS/TEN	TEN
Detachment	<10%	<10%	10-30%	>30%
Typical target lesions	Yes	No	No	No
Atypical target lesions	Yes, raised	Yes, flat (red or purpuric)	Yes, flat (red or purpuric)	Yes, flat (red or purpuric)

TEN without spots: detachment > 10%, large epidermal sheets and no purpuric macules

SJS and TEN: need to have >2 mucosal involvement (eyes, mouth, genitalia, perianal area, urethra)



Stevens-Johnson syndrome







Stevens-Johnson syndrome





Stevens-Johnson syndrome




Overlap SJS/TEN



TEN with spots



TEN with spots



TEN without spots

SJS/TEN

- <u>Drug-induced</u>: antibiotics eg.sulfonamide, anticonvulsants (carbamazipine, HLA-B*1502), allopurinol (HLA-B*5801), NSAIDs
- Infection: herpes infection, mycoplasma
- HIV infection dramatically increases the risk
- Predisposing disorder: autoimmune disease eg.
 SLE
- Malignancy: lymphoma





Figure 3. Pathogenic mechanisms involved in SJS/TEN. The schematic presents a simplified depiction of the interplay between genetics, specific components of innate and acquired immunity, and effectors of keratinocyte cell death. See text for detailed discussion. TLR3=Toll-like receptor 3. SNPs=single nucleotide polymorphisms. EP3= prostaglandin E receptor 3. (Adapted from Harp JL, Kinnebrew MA, Shinkai K.⁹⁴)

SJS/TEN

- Mortality rate SJS: 5-15%, TEN: 30-35%
- Fever
- Mucous membrane: 1-3 days before skin eruption
- Nikolsky's sign: positive
- GI and RS: profuse diarrhea, respiratory distress




Treatment of SJS/TEN

- No generally accepted regimens or treatment guideline
- · Identification/elimination of the offending drug
- Supportive measures: the mainstay of therapy
- Active therapy "disease-modifying agent"
- No controlled therapeutic trials because of infrequent and life-threatening disease
- Require complex treatment and individually adapted care

Alopecia

Cyclic phases of hair growth



3 phases


- 1. Anagen (growing phase): 2-6 yrs, 85-90% of hair on the scalp
- 2. Catagen (atrophy phase):2-3 weeks, 1%
- 3. Telogen (resting phase): 1-3 months, 10-15%
- 4. Exogen (shedding phase): hair shedding

Hair

- -Each follicle: 10-20 times of hair growth cycle in a lifetime
- -Hair color: melanocytes, eumelanin and pheomelanin




- 1.Lanugo
- 2. Vellus eg. face
- 3. Intermediate
- 4. Terminal hair





Hypertrichosis Lanuginosa Acquisita

- Sudden appearance of long, fine, nonpigmented lanugo hairs
- · Face and ears
- Most common: CA lung and colon
- AIDS, thyrotoxicosis, porphyria cutanea tarda
- Medications;
 cyclosporin, phenytoin



Hair

- -Highest density on scalp ~ 100,000
- -Distribute throughout the integument, except: palms, soles and portion of genitalia
- -Highest density of follicles: scalp-1135/cm² at birth and 615 third decade
- -Normal hair follicle

100,000/head in brown/black hair

10% greater in blondes

10% less in redheads

- -Hair growth 0.37 mm/day
- -Hair loss 100/day

Alopecia

- · Hair breakage
- · How many?
- · Acquired or congenital?
- Duration
- · Site
- · Associated symptom
- · Previous illness or postpartum
- · Blood loss or operation
- Underlying disease
- Drugs
- · Family history



Physical examination

- · Characteristic alopecia
- Scalp: scale, crust, scar, inflammation, mass, exclamation mark hair, black dot appearance
- · Hair pull
- · Hair count
- · Hair pluck
- · Microscopic examination

Evaluation

Pull test

- Grasps ~ 50-60 hairs and tugs them from proximal to distal end, 4 areas
- Positive:
 - > 2 hairs in > 1 area or 10% in 1 area
- Examined with light microscope
 - · Blunt ends: hair breakage
 - · Club hairs: telogen hair



Evaluation

Trichogram

- Proportion of anagen to catagen and telogen hairs
- Grasp 25-50 hairs with a needle holder close to the scalp and plucked sharply in the direction of the hair
- The proximal ends are place on a glass slide in a drop of water and covered with a cover slip


Forcible hair pluck






Telogen hair









Anagen hair



Trichogram evaluation



```
    Telogen count 10-25% = normal
    > 25-35% = suspicious-highly suspicious for telogen effluvium
```



-Telogen efflu**vium**

-Androgenetic

DLE, discoid lupus erythematosus LPP, lichen planopilaris (frontal fibrosing alopecia) AT, alopecia totalis AU, alopecia universalis

- LPP

Trauma

Tumor

- Tinea capitis

- Androgenetic

Anagen /telogen effluvium

1. Telogen effluvium

· diffuse alopecia with gradually progress

2. Anagen effluvium

· diffuse alopecia with rapid course

Telogen effluvium

- Sudden conversion of anagen → telogen hairs
- Often related to external causes, reverse when remove exogenous stimuli
- HPT: positive
- Trichogram: increase telogen hair > 25%
- May copresent with $AGA \rightarrow$ complicate diagnosis and treatment
- · Scalp biopsy: differentiating from diffuse AA, AGA
- · ChronicTE triggers may be difficult to identify. (esp in women between the ages of 30-60 years)

Telogen effluvium

Triggering events

Sudden onset of massive shedding (bag sign)

2-3 mo

Acute TE

TFT, CBC, ferritin, iron study, VDRL, ANA, BUN, Cr, LFT

Improve within 6 mo after triggering event or after withdrawal from suspected causal

Acute TE

Ongoing massive shedding

Chronic TE

> 6 mo

Stimulus persist > 6 mo Primary/idiopathic

Causes of telogen effluvium

Physiologic conditions

Post partum effluvium (telogen gravidarum), physiologic effluvium of new born, early stage of androgenetic alopecia

Physical or emotional stress

Severe febrile illness (eg., malaria), severe infection, crash diet, starvation, malnutrition, kwashiorkor, marasmus, malabsorption, iron deficiency, hypo or hyper- thyroidism, acrodermatitis enteropathica and acquired zinc deficiency, major surgery, traumatic accident, chronic illness (SLE, syphilis, hepatic and renal failure, etc.), advanced malignancy, chronic telogen effluvium (idiopathic), severe psychological stress (death in the family, divorce, loss of job)

Drugs


Oral retinoids, specially etretinate and acitretin, high dose contraceptive pills (OCP) or hormone replacement therapy (HRT), antithyroids, anticoagulants (especially heparin), and anticonvalescents, hypolipidemic drugs, heavy metals, beta blockers, etc.

Treatment

- Remove cause
- Ferritin level < 40 ng/dl → iron supplement
- Thyroid condition
- 2% or 5% minoxidil solution

Anagen effluvium


- Disturbance of hair follicle matrix cells
- Interrupt anagen phase
- Hair falls out 7-14 days after the initiating event without entering catagen or telogen
- Causes: chemotherapy, radiation, toxins, heavy metal, severe malnutrition
- Once the initiating trigger is removed, the hair usually regrows after around 120 days



Anagen effluvium

Alopecia areata

- Non-cicatricial alopecia
- Hair-specific autoimmune disease, with genetic factors involved in disease susceptibility and severity together with environmental factors
- T-lymphocyte interaction with follicular antigens (autoantigens)
- Chronic relapsing nature



Alopecia areata



Clinical: patches of alopecia without scarring or inflammation of scalp, HPT+


" exclamation mark hair or black dots"

- ·Alopecia totalis
- ·Alopecia universalis






 Diffuse variant: widespread thinning or may primarily affect the top of the head



Trichotillomania

"Hair pulling madness"

Rx: Psychiatist, Chloripramine





Secondary syphilis


- 1. Moth-eaten
- 2. Diffuse syphilitic
- 3. Mixed type


Dx: looking for other signs eg. mucous patch, condyloma lata, rash

Ix: VDRL

Rx: Benzathine penicillin 2.4

mu IM






Roseola syphilitica










Condyloma lata

Mucous patches

Androgenetic alopecia

- Male pattern and female pattern hair loss
- · Androgen-dependent: dihydrotestosterone
 - Conversion of scalp terminal hairs into miniaturized vellus hairs
 - Progressive decline in anagen duration, an increase in telogen duration
- · Genetic predisposition: polygenic
- The frequency and severity increase with age

Androgenetic alopecia





Pathogenesis-AGA

· MPHL

- Increase 5a-reductase activity and DHT levels
- DHT: miniaturized hair
- Genetic predisposition

· FPHL

- More complex etiology
- Androgen-related combined with genetic sensitivity
- Recommend W/U ferritin and TSH to rule out TE
- Irregular periods and/or other signs of androgen excess
 → free and total testosterone, DHEA-S

Treatment




· MPHL

- Minoxidil (2% and 5%) and finasteride (1 mg)
- Hair transplantation

· FPHL

- 2% and 5% topical minoxidil
- Oral contraceptives (to suppress ovarian androgen production), spironolactone (antiandrogen) or finasteride therapy
- Finasteride higher daily doses of 2.5 and 5 mg (can improve FPHL)

MECHANISM OF ACTION FOR ANTIANDROGENS AND FINASTERIDE



Tinea capitis

Endothrix"Black dot"

· Ectothrix



Localized scarring alopecia





Cause:

- -discoid lupus erythematosus
- -folliculitis (suppurative or fungus)
- -tumor
- -operative scar
- -cyst


Acne Vulgaris

Acne

- One of the most common dermatologic disorder
- 33% at some time between ages of 15-44 years, primarily adolescents
- Profound effect on the physical, psychological, and social wellbeing of patients
- · Impaired self-image, self-esteem
- Increased depression, anxiety, suicidal thoughts and attempts
- Effective treatment can prevent psychological distress and physical scarring

Pathogenesis of acne

- 1. Sebum production
 - Androgen (end-organ hyperresponse) Severity
- 2. Hypercornification of follicular epithelium Microcomedones
- 3. Cutibacterium acnes
 - Release chemotactic factor, complement activation
- 4. Release of inflammatory mediators into the skin
 - -IL-1a up-regulation with linoleic deficiency
 - -Synthesis of TNF-a and IL-1ß through TLR-2
 - -Autocrine and paracrine mechanism by activating AP-1



Type of acne

Non-inflammatory


- Microcomedone (acne precursor)
- Open comedone ("blackhead")
- · Closed comedone ("whitehead")

Inflammatory

- Papules, Pustules
- · Cysts, Nodules

Sequelae

- Dyspigmentation
- Scarring















How should acne be managed?

- Aim: reduce the presence and impact of symptoms including psychosocial sequelae
- Importance: acne duration and inflammation correlate to the degree of scarring
- Evaluation: treatment needs to be continued for at least 6-8 weeks before changing or adding other treatments

Acne treatment

Drugs	Mechanism
Benzoyl peroxide	Antimicrobial Weakly comedolytic
Topical retinoids	Comedolytic Anti-inflammatory
Systemic/ topical antibiotics	Antimicrobial Anti-inflammatory
Oral contraceptives	Sebosuppressive
Systemic retinoids	Comedolytic Anti-inflammatory Sebosuppressive Indirectly antimicrobial

Table 1 Algorithm for improving outcomes in acne					
		Mild	Moderate		Severe
	Comedonal	Papular/Pustular	Papular/Pustular	Nodular ^b	Nodular/Conglobate
First choice	Topical retinoid	Topical retinoid + topical antimicrobial	Oral antibiotic + topical retinoid \pm BPO	Oral antibiotic + topical retinoid \pm BPO	Oral isotretinoin ^c
Alternatives	Alt. topical retinoid or Azelaic acid ^d or Salicylic acid	Alt. topical antimicrobial + alt. topical retinoid or Azelaic acid ^d	Alt. oral antibiotic $+$ alt. topical retinoid \pm BPO	Oral isotretinoin or Alt. oral antibiotic + alt. topical retinoid ± BPO/ azelaic ^d acid	High-dose oral antibiotic + topical retinoid + BPO
Alternatives for females	See first choice	See first choice	Oral antiandrogen + topical retinoid/azelaic acid ^d ± topical antimicrobial	Oral antiandrogen $+$ topical retinoid \pm oral antibiotic \pm alt. antimicrobial	High-dose oral antiandrogen $+$ topical retinoid \pm alt. topical antimicrobial
Maintenance therapy	Topical retinoid	Topical retinoid \pm BPO	_	_	_

Abbreviations: Alt., alternative; BPO, benzoyl peroxide.

^a Consider physical removal of comedones.

Adapted from Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2010;26(Suppl 1):8; with permission.

b With small nodules (>0.5–1 cm).

^c Second course in case of relapse.

^d There was not consensus on this alternative recommendation; however, in some countries azelaic acid prescribing is appropriate practice.